Armata pharmaceuticals inc ARMP.US Overview Analysis

US StockHealth Care
(No presentation for ARMP)

ARMP AI Analysis Overview

Keys for Bullish View

  • Value≥4
  • Dividend≥2

Analysis Conclusion

The stock, with its moderate value rating, suggests that existing positions can be retained. For initiating new positions, it's advisable to wait for a value score above 4 and a dividend score of 2 or higher.

ARMP Current Performance

-3.57%

Armata pharmaceuticals inc

2.15%

Avg of Sector

0.70%

S&P500

Top 10 High Relevance to ARMP

  • CTNM Contineum therapeutics inc
    Value -Trend 2Swing Trading 2Whale Interest 3Dividend 1
    See more

ARMP Profile

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company focused on the development of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its bacteriophage-based technology. The Company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. It is advancing two lead candidates, such as AP-PA02 and AP-SA02, to address both chronic and acute bacterial infections. Its lead phage candidate, inhaled AP-PA02, is focused primarily on the treatment of chronic pulmonary infections due to Pseudomonas aeruginosa. In parallel, it has an acute bacterial infection clinical development plan focused on Staphylococcus aureus bacteremia, a difficult-to-treat and often life-threatening infection.

Price of ARMP

List of Pages